secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001171843-24-001222
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q4 2023 revenue $28.2M, guides 2024 flat-to-modest growth, margin improvement
--------------------------------------------------------------------------------

- Q4 revenue $28.2M, down 1% YoY; gross margin 58.0%, up 230 bps YoY.
- Q4 net loss $1.8M, adj. EPS $0.04; adj. EBITDA $3.6M (13% margin).
- FY2023 revenue $112.3M, down 1% YoY; adj. EBITDA $14.6M (13% vs 9.6% prior year).
- Debt reduced by $10.5M in 2023; net leverage improved from 4.0x to 2.3x.
- 2024 guidance: flat to modest revenue growth; gross margin ~60%; adj. EBITDA margin mid-teens.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324001222/0001171843-24-001222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324001222/f8k_030624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer